Vor Biopharma Inc. (VOR): Price and Financial Metrics
VOR Price/Volume Stats
| Current price | $1.71 | 52-week high | $5.70 |
| Prev. close | $1.68 | 52-week low | $1.62 |
| Day low | $1.66 | Volume | 199,057 |
| Day high | $1.74 | Avg. volume | 295,439 |
| 50-day MA | $2.05 | Dividend yield | N/A |
| 200-day MA | $2.29 | Market Cap | 116.65M |
VOR Stock Price Chart Interactive Chart >
Vor Biopharma Inc. (VOR) Company Bio
Vor BioPharma Inc. operates as a clinical stage cell therapy company. The Company specializes in developing novel therapies for treating cancer. Vor BioPharma focuses on discovering technologies that can enable selective targeting of cancer cells without impacting normal cells. Vor BioPharma serves customers in the United States.
Latest VOR News From Around the Web
Below are the latest news stories about VOR BIOPHARMA INC that investors may wish to consider to help them evaluate VOR as an investment opportunity.
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)CAMBRIDGE, Mass., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that, effective as of November 29, 2023 the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 22,875 shares of Vor Bio’s common stock and restricted stock units (“RSUs”) representing the right to receive an aggregate of 34,313 shares of Vor Bio’s common stock to four newly hired employees. The foregoing s |
Vor Bio Presents Positive Data Update on Trem-cel at HSCT² ConferencePrimary neutrophil engraftment of trem-cel achieved in all seven patients treated to dateAll three patients receiving multiple Mylotarg™ doses exhibited hematologic protection, further validating Vor Bio’s approachConference call today, November 9 at 4:30 PM ET CAMBRIDGE, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today presented updated clinical data from patients treated in VBP101, its Phase 1/2a multicenter, open-label |
Vor Bio Reports Third Quarter 2023 Financial Results and Provides Company UpdateNext trem-cel (VOR33) clinical data update expected by Relapse After Transplant and Cellular Therapy (HSCT2) Conference Nov 10-11Three oral abstracts and two poster presentations accepted at ASH 2023 Dec 9-12 CAMBRIDGE, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period ended September 30, 2023, and provided a business update. “We look forward to imminent data releases b |
Vor Bio to Participate in Upcoming Investor ConferencesCAMBRIDGE, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming investor conferences: Stifel 2023 Healthcare ConferenceFireside Chat: Tuesday, November 14, 2023 at 3:35 pm ET Location: Lotte New York Palace Hotel, New York, NY A live webcast and archived replay of the fireside chat will be available on the investors section of www.vorbio.com. 6th Annual Evercore ISI |
Multiple Clinical and Preclinical Presentations at ASH 2023 Highlight Vor Bio’s Novel eHSC and CAR-T PlatformThree oral and two poster presentations accepted by ASHCompany to host call featuring Sarah K. Tasian, MD, Associate Professor of Pediatrics at the University of Pennsylvania School of Medicine and Chief of the Hematologic Malignancies Program in the Division of Oncology at Children's Hospital of Philadelphia, to discuss abstracts today, November 2, at 9.30 AM ET. CAMBRIDGE, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, toda |
VOR Price Returns
| 1-mo | -5.00% |
| 3-mo | -24.50% |
| 6-mo | -24.34% |
| 1-year | -60.96% |
| 3-year | -93.72% |
| 5-year | N/A |
| YTD | -24.00% |
| 2023 | -66.17% |
| 2022 | -42.77% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...